<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04611607</url>
  </required_header>
  <id_info>
    <org_study_id>CAN-SHOCK</org_study_id>
    <nct_id>NCT04611607</nct_id>
  </id_info>
  <brief_title>Cangrelor in Patients With Acute Myocardial Infarction Undergoing PCI After CPR, Ventilated or Cardiogenic Shock</brief_title>
  <acronym>CAN-SHOCK</acronym>
  <official_title>Cangrelor in Patients With Acute Myocardial Infarction Undergoing PCI After CPR, Ventilated or Cardiogenic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IHF GmbH - Institut für Herzinfarktforschung</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ferrer Internacional S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>IHF GmbH - Institut für Herzinfarktforschung</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry will provide information about the efficacy and safety of cangrelor in a very&#xD;
      high-risk group of patients with acute myocardial infarction undergoing PCI. It will not only&#xD;
      include patients with cardiogenic shock, but a variety of patients not able to swallow&#xD;
      tablets, such as those after CPR and/or with invasive or non-invasive ventilation. Therefore&#xD;
      it will provide information about the use of cangrelor beyond the current knowledge.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This registry is a non-interventional, multicentre, retrospective cohort study in patients&#xD;
      with acute myocardial infarction undergoing PCI after CRP, ventilated and/or with cardiogenic&#xD;
      shock.&#xD;
&#xD;
      The study is purely observational; data will be documented retrospectively based on available&#xD;
      medical records. No additional data will be collected, no study-related treatment will be&#xD;
      initiated.&#xD;
&#xD;
      About 10 - 20 high-volume PCI clinics in Germany treating patients with myocardial infarction&#xD;
      are eligible for participation. Participating sites will be given a maximum of 6 months for&#xD;
      retrospectively documenting eligible patients.&#xD;
&#xD;
      Eligible are all patients with acute myocardial infarction (STEMI, NSTEMI) who underwent PCI&#xD;
      after CRP, ventilated and/or with cardiogenic shock and were treated with cangrelor during&#xD;
      index procedure. It is planned to enrol about 400 patients in total. Patient characteristics,&#xD;
      procedural details and clinical events occurring during the period between index MI and&#xD;
      discharge or death (whichever came first) will be documented based on the relevant existing&#xD;
      medical charts of the patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Definite stent thrombosis</measure>
    <time_frame>from procedure for index MI up to 48 hours</time_frame>
    <description>Rate of stent thromboses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recurrent myocardial infarction</measure>
    <time_frame>from procedure for index MI up to 48 hours</time_frame>
    <description>Rate of recurrent myocardial infarction according to the universal definition of MI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Definite stent thrombosis</measure>
    <time_frame>from procedure for index MI until discharge from hospital or intrahosptal death, whichever came first; up to 30 days</time_frame>
    <description>Rate of stent thromboses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent myocardial infarction</measure>
    <time_frame>from procedure for index MI until discharge from hospital or intrahosptal death, whichever came first; up to 30 days</time_frame>
    <description>Rate of recurrent myocardial infarction according to the universal definition of MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding complications</measure>
    <time_frame>from procedure for index MI until discharge from hospital or intrahosptal death, whichever came first; up to 30 days</time_frame>
    <description>Rate of bleeding complication according to BARC definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>from procedure for index MI until discharge from hospital; up to 30 days</time_frame>
    <description>Rate of death</description>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with acute myocardial infarction (STEMI, NSTEMI) undergoing PCI and treated with&#xD;
        cangrelor after CPR / in cardiogenic shock / with mechanical or non-invasive ventilation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Acute Myocardial infarction (NSTEMI or STEMI)&#xD;
&#xD;
          -  PCI with stent implantation&#xD;
&#xD;
          -  Treatment with cangrelor during index procedure&#xD;
&#xD;
          -  At least one of the following criteria:&#xD;
&#xD;
          -  CPR prior to PCI&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  Heart failure with the need for mechanical or non-invasive ventila-tion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        No explicit medical exclusion criteria are stated to avoid selection bias.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uwe Zeymer, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Ludwigshafen ; Stiftung IHF Institut für Herzinfarktforschung</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Uwe Zeymer, Prof</last_name>
    <phone>+49 621 503 4045</phone>
    <email>zeymeru@klilu.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fathema Hassinger, Dr</last_name>
    <phone>+49 621 59577 263</phone>
    <email>hassinger@ihf.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum Leverkusen</name>
      <address>
        <city>Leverkusen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter-Lothar Schwimmbeck, Prof Dr med</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigshafen</name>
      <address>
        <city>Ludwigshafen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Zeymer, Prof Dr med</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ibrahim Akin, Prof Dr med</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Maria-Hilf</name>
      <address>
        <city>Stadtlohn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allessandro Cuneo, Dr med</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2020</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

